Shots:
- The US FDA has granted 510(k) clearance to LumosityRx, a prescription digital therapeutic, designed to improve attention in adults (22-55yrs.) with attention deficit hyperactivity disorder (ADHD)
- Assessed in the GAMES Study (n>500), LumosityRx showed significantly improved TOVA Attention Comparison Score (1EP) vs a control app, with 44.2% pts achieving clinically meaningful attention gains (>1.4 points on TOVA)
- Trial also showed superior CGI-I improvement, an 8.7-point AAQoL quality-of-life gain, & improved adherence with 97% completing the 9wk. LumosityRx program
Ref: PRnewswire | Image: Lumos Labs |Press Release
Related News: Boehringer Ingelheim and Click Therapeutics Report P-III (CONVOKE) Trial Data on CT-155 for Schizophrenia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
